Q3 Loss Narrows to $129.3M as $430M in Partnership Cash Backstops Thin $164M Balance
BHVN has more than doubled off its 52-week low of $7.48.
Summary
Biohaven posted a Q3 net loss of $129.3M ($0.86 a share), narrower than the $173.4M loss a year earlier, with non-GAAP loss at $110.7M. R&D fell $39.3M year over year to $101.9M as the company reprioritized spend, which is the main driver of the smaller burn. Cash stood at roughly $164.0M on September 30 — thin relative to the quarterly loss rate, so the partnership inflows matter more than the P&L line. It already collected $80.0M from Ono on October 20 and expects $350.0M from SK Biopharmaceuticals when that deal closes, which would materially de-risk funding if it lands. The SKBP close is the number to track; until then the runway depends on the existing ATM capacity.
At the time of this announcement, BHVN was trading at $16.17 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $7.48 to $18.57. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.